';


Title 42 Part 493 → Subpart I → §493.941

Title 42 → Chapter IV → Subchapter G → Part 493 → Subpart I → §493.941

Electronic Code of Federal Regulations e-CFR

Title 42 Part 493 → Subpart I → §493.941

e-CFR data is current as of January 16, 2020

Title 42Chapter IVSubchapter GPart 493Subpart I → §493.941


Title 42: Public Health
PART 493—LABORATORY REQUIREMENTS
Subpart I—Proficiency Testing Programs for Nonwaived Testing


§493.941   Hematology (including routine hematology and coagulation).

(a) Program content and frequency of challenge. To be approved for proficiency testing for hematology, a program must provide a minimum of five samples per testing event. There must be at least three testing events at approximately equal intervals per year. The annual program must provide samples that cover the full range of values that would be expected in patient specimens. The samples may be provided through mailed shipments or, at HHS' option, may be provided to HHS and or its designee for on-site testing.

(b) Challenges per testing event. The minimum number of challenges per testing event a program must provide for each analyte or test procedure is five.

Analyte or Test Procedure

Cell identification or white blood cell differential

Erythrocyte count

Hematocrit (excluding spun microhematocrit)

Hemoglobin

Leukocyte count

Platelet count

Fibrinogen

Partial thromboplastin time

Prothrombin time

(1) An approved program for cell identification may vary over time. The types of cells that might be included in an approved program over time are—

Neutrophilic granulocytes

Eosinophilic granulocytes

Basophilic granulocytes

Lymphocytes

Monocytes

Major red and white blood cell abnormalities

Immature red and white blood cells

(2) White blood cell differentials should be limited to the percentage distribution of cellular elements listed above.

(c) Evaluation of a laboratory's analyte or test performance. HHS approves only those programs that assess the accuracy of a laboratory's responses in accordance with paragraphs (c) (1) through (5) of this section.

(1) To determine the accuracy of a laboratory's responses for qualitative and quantitative hematology tests or analytes, the program must compare the laboratory's response for each analyte with the response that reflects agreement of either 80 percent of ten or more referee laboratories or 80 percent or more of all participating laboratories. The score for a sample in hematology is either the score determined under paragraph (c) (2) or (3) of this section.

(2) For quantitative hematology tests or analytes, the program must determine the correct response for each analyte by the distance of the response from the target value. After the target value has been established for each response, the appropriateness of the response is determined using either fixed criteria based on the percentage difference from the target value or the number of standard deviations (SDs) the response differs from the target value.

Criteria for Acceptable Performance

The criteria for acceptable performance are:

Analyte or test Criteria for acceptable performance
Cell identification90% or greater consensus on identification.
White blood cell differentialTarget ±3SD based on the percentage of different types of white blood cells in the samples.
Erythrocyte countTarget ±6%.
Hematocrit (Excluding spun hematocrits)Target ±6%.
HemoglobinTarget ±7%.
Leukocyte countTarget ±15%.
Platelet countTarget ±25%.
FibrinogenTarget ±20%.
Partial thromboplastin timeTarget ±15%.
Prothrombin timeTarget ±15%.

(3) The criterion for acceptable performance for the qualitative hematology test is correct cell identification.

(4) To determine the analyte testing event score, the number of acceptable analyte responses must be averaged using the following formula:

eCFR graphic er25se06.023.gif

View or download PDF

(5) To determine the overall testing event score, the number of correct responses for all analytes must be averaged using the following formula:

eCFR graphic er25se06.022.gif

View or download PDF

[57 FR 7151, Feb. 28, 1992, as amended at 58 FR 5229, Jan. 19, 1993; 68 FR 3702, Jan. 24, 2003]